Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heiko Becker

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Transplantation and Cellular Therapy|October 11, 2020
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic LeukemiaNico Gagelmann, Rashit Bogdanov, Friedrich Stölzel, et al.
British Journal of Haematology|June 25, 2020
Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KITKhalid Shoumariyeh, Saskia Hussung, Christoph Niemöller, et al.
British Journal of Haematology|July 6, 2018
Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatmentJuliane M Stosch, Anezka Heumüller, Christoph Niemöller, et al.
Haematologica|June 12, 2013
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germlineJason H Mendler, Kati Maharry, Heiko Becker, et al.
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Diagnostics (Basel, Switzerland)|August 5, 2020
Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient ManagementJulius Wehrle, Ulrike Philipp, Martina Jolic, et al.
Blood|February 5, 2014
Tracing the development of acute myeloid leukemia in CBL syndromeHeiko Becker, Kenichi Yoshida, Nadja Blagitko-Dorfs, et al.
Annals of Hematology|September 25, 2015
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)Heiko Becker, Stefan Suciu, Björn Hans Rüter, et al.
British Journal of Haematology|November 1, 2018
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)Jürgen Krauter, Walter Fiedler, Richard F Schlenk, et al.
Pathologie (Heidelberg, Germany)|June 27, 2025
[Trop-2 expression in solid tumors : Expanded protein diagnostics within the molecular tumor board]Elaine-Pashupati Dopfer, Matthias Fahrner, Johanna Thiery, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Transplantation and Cellular Therapy|October 11, 2020
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic LeukemiaNico Gagelmann, Rashit Bogdanov, Friedrich Stölzel, et al.
British Journal of Haematology|June 25, 2020
Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KITKhalid Shoumariyeh, Saskia Hussung, Christoph Niemöller, et al.
British Journal of Haematology|July 6, 2018
Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatmentJuliane M Stosch, Anezka Heumüller, Christoph Niemöller, et al.
Haematologica|June 12, 2013
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germlineJason H Mendler, Kati Maharry, Heiko Becker, et al.
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Diagnostics (Basel, Switzerland)|August 5, 2020
Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient ManagementJulius Wehrle, Ulrike Philipp, Martina Jolic, et al.
Blood|February 5, 2014
Tracing the development of acute myeloid leukemia in CBL syndromeHeiko Becker, Kenichi Yoshida, Nadja Blagitko-Dorfs, et al.
Annals of Hematology|September 25, 2015
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)Heiko Becker, Stefan Suciu, Björn Hans Rüter, et al.
British Journal of Haematology|November 1, 2018
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)Jürgen Krauter, Walter Fiedler, Richard F Schlenk, et al.
Pathologie (Heidelberg, Germany)|June 27, 2025
[Trop-2 expression in solid tumors : Expanded protein diagnostics within the molecular tumor board]Elaine-Pashupati Dopfer, Matthias Fahrner, Johanna Thiery, et al.
Pageof 10